Below are the most recent publications written about "Mineralocorticoid Receptor Antagonists" by people in Profiles.
-
De P, Khine MT, Frankel A, Goldet G, Banerjee D, Montero RM, Chowdhury TA, Fogarty D, Karalliedde J, Mallik R, Patel DC, Wahba M, Winocour P, Zac-Varghese S, Bain S, Sharif A, Bellary S, Dasgupta I. Finerenone in the management of diabetes kidney disease. BMC Nephrol. 2025 Feb 08; 26(1):63.
-
Severino P, D'Amato A, Prosperi S, Mariani MV, Cesti? C, Myftari V, Labbro Francia A, Marek-Iannucci S, Manzi G, Filomena D, Maestrini V, Mancone M, Badagliacca R, Vizza CD, Fedele F. The Early Pharmacological Strategy with Inodilator, bEta-blockers, Mineralocorticoid Receptor Antagonists, Sodium-glucose coTransporter-2 Inhibitors and Angiotensin Receptor-neprylisin Inhibitors in Acute Heart Failure (PENTA-HF). Curr Vasc Pharmacol. 2025; 23(3):213-223.
-
Shoji S, Kaltenbach L, Granger BB, Fonarow GC, Al-Khalidi HR, Albert NM, Butler J, Allen LA, Lanfear DE, Thibodeau JT, Chapman BM, Oliver-McNeil SM, Felker GM, Pina IL, Granger CB, Hernandez AF, DeVore AD. Guideline-Directed Medical Therapy After Hospitalization for Acute Heart Failure: Insights From the CONNECT-HF. J Am Heart Assoc. 2024 Dec 17; 13(24):e036998.
-
Severino P, D'Amato A, Prosperi S, Mariani MV, Myftari V, Labbro Francia A, Cesti? C, Tomarelli E, Manzi G, Birtolo LI, Marek-Iannucci S, Maestrini V, Mancone M, Badagliacca R, Fedele F, Vizza CD. Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience. Am J Cardiovasc Drugs. 2024 Sep; 24(5):663-671.
-
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, Gonz?lez A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. Eur Heart J Cardiovasc Pharmacother. 2022 02 16; 8(2):149-156.
-
Naccarelli GV, Filippone EJ, Foy A. Do Mineralocorticoid Receptor Antagonists Suppress Atrial?Fibrillation/Flutter? J Am Coll Cardiol. 2021 07 13; 78(2):153-155.
-
Ferreira JP, Verdonschot J, Wang P, Pizard A, Collier T, Ahmed FZ, Brunner-La-Rocca HP, Clark AL, Cosmi F, Cuthbert J, D?ez J, Edelmann F, Girerd N, Gonz?lez A, Grojean S, Hazebroek M, Khan J, Latini R, Mamas MA, Mariottoni B, Mujaj B, Pellicori P, Petutschnigg J, Pieske B, Rossignol P, Rouet P, Staessen JA, Cleland JGF, Heymans S, Zannad F. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. JACC Heart Fail. 2021 04; 9(4):268-277.
-
Fiuzat M, Ezekowitz J, Alemayehu W, Westerhout CM, Sbolli M, Cani D, Whellan DJ, Ahmad T, Adams K, Pi?a IL, Patel CB, Anstrom KJ, Cooper LS, Mark D, Leifer ES, Felker GM, Januzzi JL, O'Connor CM. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2020 07 01; 5(7):757-764.
-
Kalra R, Gupta K, Sheets R, Aryal S, Ebrahimi A, Rajapreyar I, Cribbs MG, Booker OJ, Prabhu SD, Bajaj NS. Cardiac Function and Sudden Cardiac Death in Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). Am J Cardiol. 2020 08 15; 129:46-52.
-
Rahimy E, Pitcher JD, Hsu J, Adam MK, Shahlaee A, Samara WA, Vander JF, Kaiser RS, Chiang A, Spirn MJ, Fineman MS. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR). Retina. 2018 May; 38(5):962-969.